SCHEMBL12373209

SCHEMBL12373209

CCOC(=O)c1ccc(NC(=O)/C=C/c2ccccc2)cc1-c1ccccc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.61
EGFR P00533 5/20 0.56
KMT2A Q03164 4/20 0.56
MEN1 O00255 3/20 0.56
RAB9A P51151 3/20 0.56
NPC1 O15118 1/20 0.56
MMP1 P03956 7/20 0.53
MMP2 P08253 7/20 0.53
MMP9 P14780 7/20 0.53
MAOB P27338 3/20 0.53
MAOA P21397 2/20 0.53
ALDH1A1 P00352 3/20 0.52
MAPT P10636 3/20 0.52
KDM4E B2RXH2 2/20 0.52
LMNA P02545 2/20 0.51
HPGD P15428 2/20 0.51
NPSR1 Q6W5P4 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.50
MAPK1 P28482 1/20 0.50
JAK3 P52333 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12373212 0.89 NPC1 (0.70) L3MBTL1EGFRKMT2AMEN1RAB9A
SCHEMBL8751517 0.80 EGFR (0.68) L3MBTL1EGFRKMT2AMEN1RAB9A
SCHEMBL8751516 0.80 EGFR (0.68) L3MBTL1EGFRKMT2AMEN1RAB9A
SCHEMBL31453053 0.74 HIF1A (0.56) L3MBTL1EGFRKMT2AMEN1
SCHEMBL29097704 0.74 HIF1A (0.56) L3MBTL1EGFRKMT2AMEN1
SCHEMBL29097703 0.74 HIF1A (0.56) L3MBTL1EGFRKMT2AMEN1
SCHEMBL7638409 0.74 ALDH1A1 (0.53) KMT2AMEN1RAB9ANPC1ALDH1A1
SCHEMBL16221616 0.74 NPC1 (0.81) L3MBTL1EGFRKMT2AMEN1RAB9A
SCHEMBL4830396 0.73 TSHR (0.63) L3MBTL1KMT2AMEN1RAB9ANPC1
SCHEMBL18143540 0.73 CA12 (0.62) L3MBTL1KMT2AMEN1RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110201576-A1 Small molecule inhibitors of stat3 with anti-tumor activity H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2011-08-18 US disclosed
US-7960434-B2 Small molecule inhibitors of STAT3 with anti-tumor activity UNIVERSITY OF SOUTH FLORIDA (US) 2011-06-14 US disclosed
US-20090069420-A1 Small molecule inhibitors of STAT3 with anti-tumor activity H. LEE MOFFITT CANCER CENTER & RESEARCH INSTITUTE (US) 2009-03-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110201576-A1 Small molecule inhibitors of stat3 with anti-tumor activity STAT3, STAT1, STAT5A L3MBTL1 298/4885EGFR 87/4885KMT2A 3939/4885
US-20090069420-A1 Small molecule inhibitors of STAT3 with anti-tumor activity STAT3, STAT1, STAT5A L3MBTL1 298/4885EGFR 87/4885KMT2A 3939/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.